SavedAdd your journal

Journals / Turkish Journal of Biology / 2016 / Cilt: 40 - Sayı: 5

Baculoviral vector loaded mesenchymal stem cells as efficient gene therapy tools for cancer treatment

Mahmut PARMAKSIZ
Sedef Hande AKTAŞ
Ayşe Eser ELÇİN
Arzu Aktan KESKİN
Yaşar Murat ELÇİN
Arzu CİHAN ÇÖLERİ
Fikri İÇLİ
Hakan AKBULUT
Pages
1121–1128
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results showed that the recombinant baculoviral vectors can efficiently transduce mammalian cells and express genes of interest.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Insufficient targeting of the therapeutic genes to tumor cells is one of the major reasons for failure in cancer gene therapy.
📊
Key Findings & Data:The BV-CD vector treatment caused significant in vitro cytotoxicity when used with 5-fluorocytosine.
💡
Conclusion & Impact:Our results showed that the recombinant baculoviral vectors can efficiently transduce mammalian cells and express genes of interest.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Insufficient targeting of the therapeutic genes to tumor cells is one of the major reasons for failure in cancer gene therapy. Mesenchymal stem cells (MSCs) seem to be a good candidate as a carrier for gene therapy because of its selective tumor tissue-homing properties. In the current study, we constructed baculoviral vectors (BVs) carrying cytosine deaminase (CD) (BV-CD) or green fluorescence protein (GFP) genes (BV-GFP) and tested the transduction efficiency of the vectors in tumor and mesenchymal stem cells. We also tested the in vivo efficacy of the BV-CD vector in a colon cancer model. Our results showed that the recombinant baculoviral vectors can efficiently transduce mammalian cells and express genes of interest. The BV-CD vector treatment caused significant in vitro cytotoxicity when used with 5-fluorocytosine. MSCs loaded with the BV-CD vector caused a significant delay in tumor growth and increased survival when compared to control and MSC alone treated groups bearing colon cancer.

🔖

Cite This Article

PARMAKSIZ, M., AKTAŞ, S. H., ELÇİN, A. E., KESKİN, A. A., ELÇİN, Y. M., ÇÖLERİ, A. C., İÇLİ, F., AKBULUT, H. (2022). Baculoviral vector loaded mesenchymal stem cells as efficient gene therapy tools for cancer treatment. Turkish Journal of Biology, Cilt: 40 - Sayı: 5, 1121–1128. https://ajindex.com/articles/600424

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. eferencesAirenne KJ, Peltomaa E, Hytönen VP, Laitinen OH, Ylä-Herttuala S (2003). Improved generation of recombinant baculovirus genomes in Escherichia coli. Nucleic Acids Research 31: e101. Akbulut H, Ocal M, Sonugur G (2015). Cancer Gene Therapy. In: Hashad D, editor. Gene Therapy - Principles and Challenges. Rijeka, Croatia: InTech, pp. 1-36.
  2. Akbulut H, Tang Y, Akbulut KG, Maynard J, Zhang L, Deisseroth A (2006). Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer. Mol Cancer Ther 5: 1975-1985.
  3. Akbulut H, Tang Y, Zhang L, Maynard J, Pizzorn, G, Deisseroth A (2004). Vector targeting makes 5-fluorouracil chemotherapy less toxic and more effective in animal models of epithelial neoplasms. Clin Cancer Res 10: 7738-7746.
  4. Akbulut H, Zhang L, Tang Y, Deisseroth A (2003). The cytotoxic effect of replication competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon. Cancer Gene Ther 10: 388-395.
  5. Bak XY, Yang J, Wang S (2010). Baculovirus-transduced bone marrow mesenchymal stem cells for systemic cancer therapy. Cancer Gene Ther 17: 721-729.
  6. Baykan E, Koç A, Elçin AE, Elçin YM (2014). Evaluation of a biomimetic poly(e-caprolactone)/β-tricalcium phosphate multispiral scaffold for bone tissue engineering: In vitro and in vivo studies. Biointerphases 9: 029011. Bessis N, GarciaCozar FJ, Boissier MC (2004). Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Therapy 11: S10-S17. Çelebi B, Elçin YM (2009). Proteome analysis of rat bone marrow mesenchymal stem cell subcultures. J Proteome Res 8: 2164-2172.
  7. Çelebi B, Elçin AE, Elçin YM (2010). Proteome analysis of rat bone marrow mesenchymal stem cell differentiation. J Proteome Res 9: 5217-5227.
  8. Chen CY, Wu HH, Chen CP, Chern SR, Hwang SM, Huang SF, Lo WH, Chen GY (2011). Biosafety assessment of human mesenchymal stem cells engineered by hybrid baculoviral vectors. Mol Pharmaceutics 8: 1505-1514.
  9. Chuang CK, Sung LY, Hwang SM, Lo WH, Chen HC, Hu YC (2007). Baculovirus as a new gene delivery vector for stem cell engineering and bone tissue engineering. Gene Ther 14: 1417-1424.
  10. Chuang CK, Wong TH, Hwang SM, Chang YH, Chen GY, Chiu YC (2009). Baculovirus transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantation. Mol Ther 17: 889-896.
  11. Bouard D, Alaza